Profile

Aniva is among the pioneering market-maker platforms in the European Health care market that develops, produces and promotes targeted  OTx (prescribed non-prescription products), for patients with autoimmune and chronic conditions.

The prime focus: Neurology, Rheumatology, Gastroenterology, Endocrinology and Ophthalmology.

Additionally in 2014 the company developed and launched a dermatological line and the brand Anivagene. Anivagene is a specially designed and clinically validated range of Functional & Nutri-cosmetics that offer enhanced cosmetic benefits to all skin & hair needs.

To provide scientific evidence for its products and to support their efficacy and safety, Aniva International collaborates with a team of researchers and advisors, who perform randomized double-blind and placebo-controlled clinical trials and provide comprehensive scientific backing, sound bibliographical documentation and expert opinion.

The active ingredients comprise a mix of the very latest generation biomolecules such as: functional ingredients, marine biomolecules, herbal extracts, nutri-peptides, live bacteria cultures and postbiotics.

In order to enrich its product portfolio and strengthen its position in the therapeutic areas of its interest, Aniva cooperates not only with leading R&D professionals but also with various biotechnology start-ups and university incubators.

To establish its position as a regional health care player and expand geographically, Aniva has joined forces with a carefully selected network of distributors, through whom it markets and promotes its brands in numerous countries in Europe, MENA, CIS and Southeast Asia.

Finally, we believe in the future of validated biomolecules as one the majors pillars for our health care and wellbeing. And we believe in the growth potential of our targeted markets, if they are supplied with the right products and the right strategy. We have adopted a holistic view of business and pay due attention to all our stakeholders, including employees, partners, suppliers, shareholders and investors and, naturally, our end users.